BIRC5 and malignant glioma: SurVaxM has a dual mechanism of action of stimulating T-cell immunity and antibody-directed survivin pathway inhibition, stimulating the immune system to kill survivin-containing tumor cells, and has demonstrated safety and tolerability in patients with malignant glioma in a phase I study (33).